Alto Neuroscience enters $75M ATM equity offering; reports ~$168M cash as of Dec 31, 2024

Alto Neuroscience, Inc.

Entered into sales agreement with Leerink Partners for at-the-market offering of up to $75M in common stock.
Agent will receive up to 3.0% commission on shares sold; Company has no obligation to sell.
Preliminary cash and cash equivalents of ~$168M as of Dec 31, 2024; final year-end results may differ materially.
Registration statement on Form S-3 filed concurrently; ATM offering subject to SEC effectiveness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.